References
- Cook C. S., Ames G. B., Smith M. E., Kowalski K. G., Karim A. Absorption and disposition of a new antiarrhythmic agent bidisomide in man. Pharmaceutical Research 1993a; 10: 1675–1682
- Cook C. S., McDonald S. J., Karim A. Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drus. Xenobiotica 1993b; 23: 1299–1309
- Cook C. S., Rozek L. F., Hribar J., Schoenhard G. L., Karim A. Metabolism of actisomide in the dog, monkey, and man: a novel rearrangement of N-dealkylated metabolites. European Journal of Drug Metabolism and Pharmacokinetics 1992; 17: 145–154
- Desai B. N., Cook C. S., Claypool W. D., Garthwaite S. M. Bidisomide. Drugs of the Future 1992; 17: 374–376
- Frederick L. G., McDonald S. J., Garthwaite S. M. Cardiovascular profile of a new antiarrhythmic agent, SC-40230. Cardiovascular Research 1989; 23: 897–903
- Garthwaite S., Frederick L., Hatley F., Hackett A., Ruby J. Effect of SC-40230. a new class 1 antiarrhythmic agent, prevents reinduction of malignant arrhythmias in dogs. FASEB Journal 1989a; 3: A1020
- Garthwaite S., Hatley F., Frederick L., Ruby J., Cook C. Effect of SC-40230, a new class I antiarrhythmic agent, on canine ventricular tachycardia. Drug Development Research 1989b; 17: 119–134
- Karim A., Ranney R. E., Kraychy S. Metabolism of disopyramide in the dog. Journal of Pharmaceutical Science 1972; 61: 888–893
- Spinelli W., Hoffman B. Mechanism of termination of reentrant atrial arrhythmia by class I and class III arrhythmic agents. Circulation Research 1989; 65: 1565–1579